linerixibat
Mar 27, 2026
GSK’s LYNAVOY Enters PBC Treatment Space, Targeting High-Burden Pruritus Segment
Summary LYNAVOY is an oral IBAT inhibitor approved to treat cholestatic pruritus in adults with PBC, making it the first medicine in the US specifically cleared for this indication. Up to 89% of people with PBC experience cholestatic pruritus, an internal, often unbearable itch that can disrupt sleep, aggrav...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
